Serina Therapeutics, Inc. (SER) - 10-Q Summary
Business Context and Reporting Period
Period: Quarter and nine months ended September 30, 2025.
Company Profile: Serina Therapeutics is a clinical-stage biotechnology company developing drug candidates for neurological diseases using its proprietary POZ drug delivery technology. The company operates as a single segment focused on research and development.
Recent Corporate Action: The company completed a reverse recapitalization merger in March 2024 and changed its name from AgeX Therapeutics, Inc. to Serina Therapeutics, Inc.
Key Financial Metrics
| Metric (in thousands) | Q3 2025 | Q3 2024 | 9M 2025 | 9M 2024 |
|---|---|---|---|---|
| Revenues | $0 | $14 | $130 | $70 |
| Net Loss | $(4,595) | $1,383 (Income) | $(15,879) | $(8,455) |
| Net Loss Attributable to Serina | $(4,585) | $1,410 | $(15,846) | $(8,401) |
| Operating Expenses | $6,392 | $5,326 | $17,945 | $11,569 |
| Cash and Cash Equivalents | $8,620 (as of Sept 30, 2025) | |||
| Accumulated Deficit | $(60,164) (as of Sept 30, 2025) | |||
| Convertible Note Liability (Current) | $2,888 (Net of discount) | |||
| Warrant Liability (Total) | $3,558 ($1,676 Current + $1,882 Non-current) |
Material Changes vs. Prior Period
- Net Loss Expansion: The company reported a net loss of $4.6 million for Q3 2025, compared to a net income of $1.4 million in Q3 2024. This shift is primarily due to a significant decrease in non-cash gains from the change in fair value of warrant liabilities ($1.0 million gain in Q3 2025 vs. $6.7 million gain in Q3 2024).
- Operating Expenses: Total operating expenses increased by $1.1 million in Q3 2025 compared to the prior year, driven by a $1.2 million increase in Research and Development (R&D) expenses. R&D growth was attributed to increased outsourced research services, consultant spend, and amortization of a prepaid technology access fee.
- Liquidity Position: Cash and cash equivalents increased from $3.7 million at year-end 2024 to $8.6 million as of September 30, 2025, following financing activities including a $5.0 million drawdown on a new convertible note and proceeds from an at-the-market (ATM) offering.
- Debt Structure: The company entered into a new $20 million unsecured convertible note facility in September 2025, drawing the first tranche of $5.0 million. This replaced previous reliance on secured notes held by related parties.
Guidance, Outlook, Risks, and Unusual Items
- Going Concern Warning: Management has expressed substantial doubt about the company's ability to continue as a going concern. Cash on hand ($8.6 million) is not expected to be sufficient to fund operations for the next 12 months. Additional financing is required to continue development.
- FDA Clinical Hold: On November 3, 2025, the FDA placed a clinical hold on the Investigational New Drug (IND) application for SER-252, the company's lead program for advanced Parkinson's disease. The hold relates to a commonly used excipient in the formulation, not the active drug substance. This delays the planned registrational clinical study and impacts the ability to draw future tranches of the 2025 Convertible Note tied to clinical milestones.
- Financing Activities: The company raised capital through the issuance of Series A Convertible Preferred Stock ($4.9 million net proceeds in April 2025) and an ATM program ($2.2 million net proceeds YTD). The 2025 Convertible Note bears 10% interest and includes contingent warrants.
- Internal Control Weaknesses: The company identified material weaknesses in internal controls over financial reporting, citing a lack of qualified accounting personnel, inadequate segregation of duties, and reliance on manual processes. A remediation plan is underway.
Investor Verification Checklist
- Cash Runway: Verify the timeline for the next financing round given the "substantial doubt" disclosure and the $8.6 million cash balance.
- FDA Resolution: Monitor communications regarding the resolution of the clinical hold on SER-252, as this is a prerequisite for drawing the remaining $15 million of the 2025 Convertible Note.
- Dilution Risk: Assess the potential dilution from the 2025 Convertible Note (convertible at $5.18/share) and the associated contingent warrants (100% of shares issuable upon conversion).
- Internal Controls: Review the progress of the remediation plan for material weaknesses in financial reporting to ensure future filing reliability.
- Warrant Liability Volatility: Note that net income/loss is heavily influenced by non-cash fair value adjustments of warrant liabilities, which can obscure operational performance.